跳至主要内容
临床试验/NCT02962830
NCT02962830已完成2 期

Assessment of Fetal and Maternal Sufentanil Pharmacokinetics After Intra-amniotic Injection

University Hospital, Lille1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2017年4月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
8
试验地点
1
主要终点
fetal plasma concentrations

研究概览

简要总结

The fetus may be exposed during pregnancy to nociceptive stimuli because of fetal pathology (e.g., malformation) or a diagnostic or therapeutic procedure.

To date, there is very little data and no consensus on fetal analgesia. The aim of the investigators study is to evaluate the pharmacokinetics of Sufentanil after intra amniotic injection.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Termination of pregnancy for fetal malformation
  • Gestational age > 24 weeks of gestation

排除标准

  • Multiple pregnancy
  • Allergy or contraindication to sufentanil
  • Morphinic addiction
  • fetal gastroschisis, omphalocele or swallowing disorder
  • maternal cardiac or respiratory distress

研究组 & 干预措施

Sufentanil

Experimental

干预措施: Sufentanil (Drug)

结局指标

主要结局

fetal plasma concentrations

时间窗: at 30 minutes after intra-amniotic injection

fetal plasma concentrations of morphine derivatives by Ultrahigh Pressure Liquid Chromatography (UPLC) with mass spectometry (Triple Quadrupole Detector)

次要结局

  • amniotic fluid concentrations(Immediately within 5 min after intra-amniotic injection)
  • Maternal plasma concentrations(at 30 minutes and at 1, 2, 4, 8, 24 hours after intra-amniotic injection)

研究者

发起方
University Hospital, Lille
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验